Algert Global LLC Takes $2.65 Million Position in Pfizer Inc. $PFE

Key Points

• Algert Global LLC has recently acquired a $2.65 million position in Pfizer Inc., purchasing 104,428 shares as part of their investment strategy.
• Pfizer reported earnings of $0.78 per share for the last quarter, exceeding analyst expectations, with a significant revenue increase of 10.3% year-over-year.
• The company declared a quarterly dividend of $0.43, representing a 6.8% yield, with a dividend payout ratio of 91.49% currently.

Algert Global LLC purchased a new position in Pfizer Inc. (NYSE:PFE - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 104,428 shares of the biopharmaceutical company's stock, valued at approximately $2,646,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Clarity Asset Management Inc. purchased a new stake in shares of Pfizer in the fourth quarter valued at approximately $27,000. Gould Capital LLC raised its position in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. purchased a new stake in shares of Pfizer in the 1st quarter worth $27,000. North Capital Inc. bought a new position in shares of Pfizer during the 1st quarter worth $28,000. Finally, Bayforest Capital Ltd purchased a new position in shares of Pfizer during the first quarter valued at $28,000. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Up 0.2%

NYSE:PFE opened at $25.3750 on Thursday. The stock has a market capitalization of $144.27 billion, a price-to-earnings ratio of 13.50, a PEG ratio of 0.90 and a beta of 0.52. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a 50 day moving average of $24.66 and a 200 day moving average of $24.42.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the previous year, the company earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is currently 91.49%.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on PFE shares. HSBC lowered their price objective on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Citigroup upped their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. The Goldman Sachs Group increased their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 30th. UBS Group boosted their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research note on Wednesday, April 30th. Finally, Leerink Partners lowered their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus target price of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.